Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
J Viral Hepat ; 22 Suppl 1: 46-73, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25560841

ABSTRACT

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries, and the relative impact of two scenarios was considered: (i) increased treatment efficacy while holding the treated population constant and (ii) increased treatment efficacy and increased annual treated population. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. In most countries, the annual treated population had to increase several fold to achieve the largest reductions in HCV-related morbidity and mortality. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. In most of the studied countries, the majority of patients were born between 1945 and 1985.


Subject(s)
Antiviral Agents/therapeutic use , Cost of Illness , Hepatitis C, Chronic/drug therapy , Mass Screening , Models, Biological , Disease Progression , Global Health , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/epidemiology , Humans , Prevalence , Treatment Outcome
2.
J Viral Hepat ; 22 Suppl 1: 26-45, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25560840

ABSTRACT

Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was used to determine current treatment levels and outcomes in each country. In most countries, viremic prevalence has already peaked. In every country studied, prevalence begins to decline before 2030, when current treatment levels were held constant. In contrast, cases of advanced liver disease and liver related deaths will continue to increase through 2030 in most countries. The current treatment paradigm is inadequate if large reductions in HCV related morbidity and mortality are to be achieved.


Subject(s)
Antiviral Agents/therapeutic use , Cost of Illness , Hepatitis C, Chronic/epidemiology , Models, Biological , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Disease Progression , Female , Global Health , Hepatitis C, Chronic/drug therapy , Humans , Infant , Infant, Newborn , Male , Middle Aged , Prevalence , Young Adult
3.
Ter Arkh ; 70(10): 48-51, 1998.
Article in Russian | MEDLINE | ID: mdl-9864805

ABSTRACT

AIM: To assess benefit for children with malignant blood disease (MBD) of the hepatoprotector heptral. MATERIALS AND METHODS: 67 children with blood malignancy aged 3-14 years were examined (53 of them had acute lymphoblastic leukemia). 39 patients were in the study group (25 of them had hepatitis B or C), 28 were controls. Initially, heptral was injected intravenously (14 days) then orally (16-30 days). Activity of transaminases and number of violations of polychemotherapy protocols because of hepatic toxicity were registered. RESULTS: Heptral administration led to inhibited activity of AlAT and AsAT especially in non-infected patients. Protocol deviations became less frequent. CONCLUSION: Heptral is a potent hepatoprotector in hepatic lesions of toxic, viral and mixed origin.


Subject(s)
Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Hematologic Neoplasms/complications , Liver Diseases/drug therapy , S-Adenosylmethionine/therapeutic use , Adolescent , Antineoplastic Agents/adverse effects , Biomarkers/blood , Child , Child, Preschool , Drug Administration Routes , Follow-Up Studies , Hematologic Neoplasms/drug therapy , Hematologic Neoplasms/enzymology , Humans , Liver Diseases/complications , Liver Diseases/enzymology , Male , Retrospective Studies , S-Adenosylmethionine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...